A decade is how far ahead genetic changes in blood cells may signal a blood cancer's trajectory, Orlando Health oncologist Abhishek Chilkulwar, M.D. said, commenting on a Cancer Discovery study that followed 30 myeloproliferative neoplasm patients. Nine of the 30 eventually developed acute myeloid leukemia; three carried a diagnosis of triple-negative essential thrombocythemia but showed no genetic cancer markers at all.
What the study measured
Myeloproliferative neoplasms (MPNs) are a group of blood cancers in which the bone marrow produces too many blood cells. Researchers at the Wellcome Trust Sanger Institute in the U.K. monitored DNA in patients' blood and bone marrow for genetic changes, then mapped those changes against clinical outcomes: stable disease, progression to myelofibrosis, or progression to acute leukemia.
Patients who stayed stable tended to carry stable DNA. Those whose disease worsened often showed new clusters of abnormal cells emerging years before routine blood tests detected any change.
How the 9 AML cases diverged
The nine participants who developed acute myeloid leukemia did not follow a single path. In some, MPN cells gradually accumulated harmful mutations. In others, leukemia appeared to arise from a separate population of abnormal blood cells. A similar split appeared among patients who developed myelofibrosis. That divergence matters because it suggests disease progression has no single, predictable escalator.
Drug signatures and a reclassification question
Two common MPN drugs left recognizable DNA patterns in the data. Hydroxyurea, used to control blood counts, produces a characteristic signature of small DNA changes. Azacitidine, used to treat certain blood cancers, shows a similar pattern. Neither was found to cause leukemia.
The three triple-negative essential thrombocythemia cases complicate the picture further. Researchers found no genetic cancer markers in those patients' samples, raising the question of whether some patients carrying that diagnosis have a malignant disease at all.
Near-term use: monitoring, not transplant
Chilkulwar, who was not involved in the study, called it a "striking demonstration" that a patient's future disease path may be written in DNA long before blood work shows anything unusual. The realistic near-term application: shifting high-risk patients to more frequent blood counts and, where warranted, more frequent bone marrow checks. Stem cell transplant remains reserved for patients who have actually progressed to myelofibrosis or AML. The cohort of 30 limits what can be concluded; the study establishes associations, not cause and effect. The next step, Chilkulwar said, would pair genetic early warning with drugs targeting those specific mutations.